跳转至内容
Merck
CN

SML2805

水仙环素

≥98% (HPLC), Rho/Rho kinase/LIM kinase/cofilin signaling pathway activator, powder

别名:

Narciclasine, (2S-(2-alpha,3-beta,4-beta,4a-beta))-3,4,4a,5-tetrahydro-2,3,4,7-tetrahydroxy-(1,3)Dioxolo(4,5-j)phenanthridin-6(2H)-one, 3,4,4a,5-Tetrahydro-2,3,4,7-tetrahydroxy-(1,3)dioxolo(4,5-j)phenanthridin-6(2H)-one, BRN 1087400, Lycoricidin-A, Lycoricidinol, NSC 266535

登录 查看公司和协议定价

选择尺寸

关于此项目

经验公式（希尔记法）:
C14H13NO7
化学文摘社编号:
29477-83-6
分子量:
307.26
MDL编号:
MFCD01729949
UNSPSC代码:
12352200
NACRES:
NA.77

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

水仙环素, ≥98% (HPLC)

质量水平

100

方案

≥98% (HPLC)

表单

powder

旋光性

[α]/D 167 to 187° in DMSO

颜色

white to beige

溶解性

DMSO: 2 mg/mL, clear

储存温度

−20°C

SMILES字符串

O[C@H]1C=C2[C@@H](NC(=O)c3c(O)c4OCOc4cc23)[C@H](O)[C@@H]1O

InChI

1S/C14H13NO7/c16-6-1-5-4-2-7-13(22-3-21-7)11(18)8(4)14(20)15-9(5)12(19)10(6)17/h1-2,6,9-10,12,16-19H,3H2,(H,15,20)/t6-,9+,10+,12-/m0/s1

InChI key

LZAZURSABQIKGB-AEKGRLRDSA-N

正在寻找类似产品? 访问 产品对比指南

相关类别

生化/生理作用

Narciclasine is a Rho/Rho kinase/LIM kinase/cofilin signaling pathway activator. Also narciclasine is an actin stress fiber formation inducer; a plant growth modulator.
Recent report in Blood Identified cinobufagin, anisomycin and narciclasine as novel expression-mimickers (Ems) that exert in vitro as well as in vivo anti-AML efficacy against AML expressing mtRUNX1. Recent report identifies cinobufagin, anisomycin and narciclasine as novel expression-mimickers (Ems) that exert in vitro as well as in vivo anti-AML efficacy against AML expressing mtRUNX1.

象形图

Skull and crossbones
GHS06

警示用语：

Danger

危险声明

H301

危险分类

Acute Tox. 3 Oral

储存分类代码

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

涉药品监管产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000233402
0000233402
0000119183
0000119184
0000097241

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Anna Stark et al.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 33(8), 8771-8781 (2019-04-25)
The alkaloid narciclasine has been characterized extensively as an anticancer compound. Accumulating evidence suggests that narciclasine has anti-inflammatory potential; however, the underlying mechanism remains poorly understood. We hypothesized that narciclasine affects the activation of endothelial cells (ECs), a hallmark of
Florence Lefranc et al.
Molecular cancer therapeutics, 8(7), 1739-1750 (2009-06-18)
Cell motility and resistance to apoptosis characterize glioblastoma multiforme growth and malignancy. Narciclasine, a plant growth modulator, could represent a powerful new weapon targeting the Achilles' heel of glioblastoma multiforme and may offer the potential to better combat these devastating
Christopher P Mill et al.
Blood, 134(1), 59-73 (2019-04-27)
RUNX1 transcription factor regulates normal and malignant hematopoiesis. Somatic or germline mutant RUNX1 (mtRUNX1) is associated with poorer outcome in acute myeloid leukemia (AML). Knockdown or inhibition of RUNX1 induced more apoptosis of AML expressing mtRUNX1 versus wild-type RUNX1 and

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持